Evidence map›Paper›PMID 34135970›Full record

ArticleInternational journal of biomaterials2021

Development and Characterization of Stingless Bee Propolis Properties for the Development of Solid Lipid Nanoparticles for Loading Lipophilic Substances.

Putthiporn Khongkaew, Watcharaphong Chaemsawang

Open access · goldAbstract read
In one paragraph

Article in International journal of biomaterials, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Biomedical reports · 2024
    Article
  2. Article
  3. Review
  4. Review
  5. Stingless Bee Propolis: New Insights for Anticancer Drugs.Oxidative medicine and cellular longevity · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Putthiporn KhongkaewDepartment of Pharmacognosy and Pharmaceutical Chemistry, Faculty of Pharmaceutical Science, Burapha University, 169 Long-Hard Bangsaen Road, Saen Sook Sub-District, Mueang District, Chonburi 20131, Thailand.ORCID https://orcid.org/0000-0002-5717-7638
Watcharaphong ChaemsawangDepartment of Pharmaceutical Technology, Faculty of Pharmaceutical Science, Burapha University, 169 Long-Hard Bangsaen Road, Saen Sook Sub-District, Mueang District, Chonburi 20131, Thailand.ORCID https://orcid.org/0000-0002-1154-9344
Burapha University · TH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stingless bees are insects which are popularly bred by agriculturists in the eastern region of Thailand for the pollination of their orchards. The products from stingless bee breeding include bee honey and bee propolis. The objective of this experiment is to study the possibility of developing stingless bee propolis wax into solid lipid nanoparticles (SLN) by the comparison of five surfactants (Brij 721, Cremophor WO 7, Myrj 52, Poloxamer 188, and Tween 80). Each surfactant is used at three concentrations: 10%, 20%, and 30%. A master formula is selected according to the following: physical features, particle size, zeta potential, and entrapment. The results showed that Brij 721 and Myri 52 at 20% can be used in preparing SLN and have good preservation properties for vitamin E (size: 451.2 nm and 416.8 nm, zeta potential: - 24.0 and - 32.7; % EE: 92.32% and 92.00%, resp.). Therefore, they are further developed by adding the following drugs at low solubility: curcumin, ibuprofen, and astaxanthin. It is found that a formula using the surfactants Brij 721 and Myrj 52 at 20% have similar drug entrapment. The entrapment study involves curcumin 82%, ibuprofen 40%, and astaxanthin 67%. Moreover, the cytotoxicity test of blank solid lipid nanoparticle found no toxicty in fibroblast cell line (CRL-2522). Therefore, from this study, it is determined that stingless bee propolis wax has the potential to be developed to provide more efficient SLN in the future.

Identifiers

PMID34135970
PMCPMC8177972
OpenAlexW3169704541

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.